Abivax seeks funds to follow another fork
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.
